VRNA Form 4: Director disposes shares as takeover pays $107 per ADS
Rhea-AI Filing Summary
Director David R. Ebsworth reported multiple transactions tied to the completion of a scheme of arrangement for Verona Pharma plc (VRNA) on 10/07/2025. Large blocks of ordinary shares were disposed of as part of the Scheme, and time‑based restricted share units were accelerated and converted into cash. Each ADS represents eight ordinary shares and received $107 in cash at the Effective Time, reflecting $13.375 per ordinary share. Following the transactions and RSU conversions, the reporting person shows 72,000 ordinary shares beneficially owned directly. Certain holdings were held indirectly by Ebsworth GmbH and were also disposed.
Positive
- RSU acceleration and cash conversion provided immediate liquidity for award holders (72,000 ADS equivalent)
- Clear takeover consideration of $13.375 per ordinary share (ADS Consideration $107) removes execution uncertainty for holders
Negative
- Major disposals reported (e.g., 880,499 and 617,600 ordinary shares) reduced insider equity exposure materially
- Indirect holdings by Ebsworth GmbH were also disposed, indicating the transaction affected both direct and indirect positions
Insights
TL;DR: Director participated in a cash takeover exit; RSUs accelerated and cashed out.
The transactions reflect the closing mechanics of a takeover: the Scheme of Arrangement paid $13.375 per ordinary share, with ADS holders receiving $107 per ADS because each ADS equals eight ordinary shares. Large share disposals reported by the director are tied explicitly to that Scheme and the related Transaction Agreement dated 07/08/2025.
Risks and dependencies include withholding taxes and the exact allocation between direct and indirect holdings; the RSU awards were automatically converted into cash at the Effective Time. Monitor any subsequent Form 4 filings for further transfers or residual holdings changes over the near term.
TL;DR: Time‑based RSUs vested and converted into cash as part of the deal; 72,000 RSU‑equivalent ADSs were involved.
Under the Transaction Agreement, outstanding time‑based RSU awards became fully vested immediately prior to the Effective Time and converted into a cash payment equal to the number of ADSs underlying the award multiplied by the ADS Consideration. The filing shows an RSU award equivalent of 72,000 ADSs that resulted in a cash entitlement.
This is a standard change‑of‑control settlement of equity awards; stakeholders should note the cash treatment and the RSUs' lack of expiration. Expect any tax withholding details to appear on payroll or tax statements rather than in this Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 880,499 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 617,600 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
